Cardiology Research and Practice

Clinical Study

Acute Experimental Hyperthyroidism Does Not Affect Basal and Volume-Induced Atrial Natriuretic Peptide Secretion in Healthy Subjects

Table 2

Echocardiographic characteristics of the study population before and after T3 administration.
ParameterBefore T3After T3P value
Left atrial diameter, cm 3 . 3 8 ± 0 . 2 5 3 . 3 1 ± 0 . 2 7 .660
LV end-systolic diameter, cm 3 . 3 2 ± 0 . 2 5 3 . 0 9 ± 0 . 2 6 .024
LV end-systolic volume, mL 4 5 . 5 ± 8 . 2 3 8 . 2 ± 7 . 5 .034
Shortening fraction, % 3 3 . 6 ± 0 . 9 3 9 . 6 ± 2 . 8 .002
Ejection fraction, % 6 2 . 1 ± 1 . 4 6 9 . 8 ± 3 . 4 .001
Mean V(cf) shortening, circ/sec 1 . 1 4 ± 0 . 0 7 1 . 4 3 ± 0 . 1 1 < .001
Stroke volume, mL 7 3 . 8 ± 1 0 . 7 8 7 . 1 ± 1 2 . 1 .010
Stroke index, mL/m2 3 7 . 6 ± 6 . 7 4 6 ± 5 . 9 .049
LV ejection time, msec 2 8 4 . 7 ± 2 0 . 4 2 6 8 ± 1 4 . 4 .069
Cardiac output, L/min 4 . 9 7 ± 0 . 6 2 6 . 5 1 ± 0 . 9 8 .038
LV PET/ET ratio 0 . 2 7 ± 0 . 0 6 0 . 2 8 ± 0 . 0 3 .749
Peak 𝐸 velocity, m/sec 0 . 7 3 ± 0 . 1 3 0 . 5 9 ± 0 . 1 2 .006
Peak 𝐴 velocity, m/sec 0 . 4 4 ± 0 . 0 4 0 . 4 8 ± 0 . 0 5 .440
Acceleration velocity, m/sec2 7 . 3 ± 1 . 6 5 . 2 ± 1 . 8 .018
SVR, mmHg·mL−1 ⋅ min−1 2 4 . 5 ± 2 . 9 1 8 . 2 ± 2 . 7 .046
LV: left ventricular; PET/ET: pre-ejection/ejection time; SVR: systemic vascular resistance; V(cf): velocity of circumference fiber.